Consolidated Planning Corp Sells 1,193 Shares of LeMaitre Vascular, Inc. $LMAT

Consolidated Planning Corp reduced its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 10.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,093 shares of the medical instruments supplier’s stock after selling 1,193 shares during the quarter. Consolidated Planning Corp’s holdings in LeMaitre Vascular were worth $838,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in LMAT. Annex Advisory Services LLC increased its stake in LeMaitre Vascular by 535.2% in the 2nd quarter. Annex Advisory Services LLC now owns 219,667 shares of the medical instruments supplier’s stock valued at $18,243,000 after buying an additional 185,085 shares during the last quarter. Millennium Management LLC increased its stake in LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares during the last quarter. Invesco Ltd. increased its stake in LeMaitre Vascular by 34.5% in the 1st quarter. Invesco Ltd. now owns 235,436 shares of the medical instruments supplier’s stock valued at $19,753,000 after buying an additional 60,438 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after buying an additional 55,804 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in LeMaitre Vascular in the 1st quarter valued at $4,631,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Down 1.0%

Shares of LMAT opened at $86.67 on Thursday. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The firm has a market cap of $1.96 billion, a P/E ratio of 42.07, a price-to-earnings-growth ratio of 2.25 and a beta of 0.78. The firm’s 50-day simple moving average is $91.43 and its 200 day simple moving average is $86.24. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. During the same quarter in the prior year, the business earned $0.52 EPS. LeMaitre Vascular’s quarterly revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were paid a $0.20 dividend. The ex-dividend date was Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is 38.83%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Barrington Research reiterated an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research note on Tuesday, September 23rd. Cantor Fitzgerald lifted their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $97.60.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the sale, the chief executive officer owned 1,727,003 shares of the company’s stock, valued at $161,492,050.53. The trade was a 5.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John A. Roush sold 6,561 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the sale, the director directly owned 2,916 shares of the company’s stock, valued at $269,875.80. This represents a 69.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,815 shares of company stock worth $11,280,206 in the last quarter. Corporate insiders own 9.50% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.